Premium
Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma
Author(s) -
Byrne Michael J.
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197611)38:5<1922::aid-cncr2820380509>3.0.co;2-2
Subject(s) - procarbazine , medicine , vincristine , cyclophosphamide , melanoma , oncology , regimen , toxicity , chemotherapy , cancer research
Patients with advanced malignant melanoma were randomly assigned to treatment with cyclophosphamide and vincristine (CV) or cyclophosphamide, vincristine, and procarbazine (CVP). The objective response rates to each regimen (CV 30%, CVP 33%) were the same. Patients with disease confined to skin, subcutaneous tissue nodes, lung, or pleura had a significantly superior response rate to that in those with disease involving liver, bone or brain. The survival of responders was superior to that of nonresponders. The efficacy and moderate toxicity of CV suggests that further work with this combination in malignant melanoma is indicated.